Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €23.36 EUR
Change Today -0.53 / -2.22%
Volume 5.2K
FYB On Other Exchanges
Symbol
Exchange
Xetra
As of 2:30 PM 09/1/15 All times are local (Market data is delayed by at least 15 minutes).

formycon ag (FYB) Snapshot

Open
€23.96
Previous Close
€23.89
Day High
€24.23
Day Low
€23.36
52 Week High
04/10/15 - €35.00
52 Week Low
09/2/14 - €6.79
Market Cap
211.7M
Average Volume 10 Days
25.8K
EPS TTM
€0.09
Shares Outstanding
9.1M
EX-Date
--
P/E TM
248.8x
Dividend
--
Dividend Yield
--
Current Stock Chart for FORMYCON AG (FYB)

Related News

No related news articles were found.

formycon ag (FYB) Related Businessweek News

No Related Businessweek News Found

formycon ag (FYB) Details

Formycon AG develops and markets biosimilar products. It also provides specialized services to pharma- and biotech companies. The company was formerly known as Nanohale AG and changed its name to Formycon AG in 2012. Formycon AG was founded in 1999 and is based in Planegg, Germany.

Founded in 1999

formycon ag (FYB) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

formycon ag (FYB) Key Developments

Formycon AG Receives Favorable Scientific Advice from U.S. Food and Drug Administration for its Partnered Biosimilar Candidate FYB201

Formycon AG has received a scientific advice letter from the U.S. Food and Drug Administration (FDA) regarding the preclinical and clinical development program for FYB201, the first biosimilar product candidate to emerge from its development pipeline, following the receipt of similarly favorable scientific advice from the European Medicines Agency (EMA) in December 2014. In its letter, the FDA, like the EMA, expresses its support for the company's proposed approach to proceed with FYB201 directly to the pivotal phase III clinical trial. Based upon the scientific advices received from the EMA and FDA, Formycon and its license partner Bioeq GmbH are now in a position to carry forward with a clinical study design for a global phase III trial which will enable them to apply simultaneously for regulatory approval in both the U.S. and European Union. All preclinical activities and the preparations for the phase III trial for FYB201 are moving forward according to plan. The market launch of FYB201 in the highly regulated markets, particularly the U.S. and European Union, is planned to begin starting from 2020.

Formycon AG Announces Consolidated Earnings Results for the First Quarter of 2015; Provides Earnings Guidance for the Year 2015

Formycon AG announced consolidated earnings results for the first quarter of 2015. For the quarter, the company reported revenues of EUR 3.0 million compared to EUR 5.8 million a year ago. The decline was due to the fact that the prior-year period included a one-time payment following the signing of the above-mentioned licensing agreement. LBITDA was EUR 0.3 million compared to EBITDA of EUR 4.2 million a year ago, with the decline likewise attribute to the one-time payment in the prior-year period. The company announced its financial results, reflecting the continued advances of its biosimilar development projects in line with plan. The group's revenue for the period was largely attributable to its licensing and development agreement with Santo Holding GmbH for FYB201, the first of its biosimilar drug projects. Based upon the recently announced successful signing of a partnership deal for FYB203, the company has raised its full-year forecast for fiscal year 2015, which it now expects to end with positive EBITDA.

Formycon AG Signs Licensing Agreement for its FYB203 Biosimilar Drug

Formycon AG has announced the signing of an exclusive, global out-licensing deal for its FYB203 biosimilar drug, with Santo Holding GmbH as licensing partner. The newly signed agreement will ensure that Formycon has project funding in place all the way through to market introduction. Under the agreement, Santo Holding will assume responsibility for, and the costs of, all further development activities, production and marketing of the Formycon biosimilar drug. In return, Santo Holding will receive exclusive worldwide marketing rights for FYB203. Pharmaceutical product development through to regulatory approval will remain in the hands of Formycon, while clinical development will be carried out by Bioeq GmbH, which manages biosimilar product development activities on behalf of Santo Holding. Under the terms of the new agreement, Formycon will receive an immediate payment in the amount of several millions, along with ongoing payment for its product development activities through to regulatory approval.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
FYB:GR €23.36 EUR -0.53

FYB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for FYB.
View Industry Companies
 

Industry Analysis

FYB

Industry Average

Valuation FYB Industry Range
Price/Earnings 100.0x
Price/Sales 15.3x
Price/Book 14.7x
Price/Cash Flow 105.1x
TEV/Sales 15.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact FORMYCON AG, please visit www.formycon.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.